MESO PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

MESO ▼ -8.32% at T+20d

LONG call ✗ call lost -8.32% · α vs SPY -14.36% · entry $15.75 → $14.44

Next anchor: T+60d in 29d

Last close $13.80 (close Jun 8) · -12.38% from $15.75 entry

Entry anchored
Apr 14, 03:59 PM ET
via Databento tick

T+1d

+2.16%

call +2.16% · α +1.91%

$16.09

settled 8w ago

T+5d

-0.06%

call -0.06% · α -1.70%

$15.74

settled 7w ago

T+20d

-8.32%

call -8.32% · α -14.36%

$14.44

settled 29d ago

T+60d

—

call — · α —

—

in 29d

Price Chart

Loading chart...

Executive Summary

Mesoblast announced an exclusive worldwide license to a patented CAR-MSC technology platform from Mayo Clinic, acquired via issuance of ASX ordinary shares. The deal enhances Mesoblast's cell therapy pipeline with potential for improved targeting in inflammatory diseases like ulcerative colitis, Crohn’s, and lupus nephritis.

Actionable Insight

The CAR-MSC platform significantly strengthens Mesoblast’s R&D pipeline and technological moat in allogeneic cell therapy. While share issuance introduces dilution, the absence of cash cost and addition of high-potential IP makes this a strategically positive move. Monitor upcoming preclinical data and potential clinical milestones as key catalysts.

Key Facts

Mesoblast acquired exclusive worldwide rights to a CAR-MSC technology platform developed at Mayo Clinic.
The acquisition was made through issuance of ASX ordinary shares (no cash outlay disclosed).
Technology aims to enhance MSC homing and potency in inflammatory and autoimmune diseases, including bowel diseases and lupus nephritis.
Mayo Clinic will provide in-kind support, including GMP manufacturing assistance.
Mayo Clinic holds financial interest in the technology via licensing agreement.

Financial Impact

Undisclosed dilution from share issuance; no cash outflow reported.

dilutionintellectual_propertyR&D_pipeline

Risk Factors

Dilution risk from share-based acquisition, magnitude unknown.
Early-stage technology: CAR-MSC is preclinical, with no guarantee of clinical success.
Forward-looking statements dominate; near-term financial impact is minimal.

Market Snapshot

Exchange

OTC

Sector

Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3274064

5 reports for MESO

T+1T+5T+20T+60

100% Hit rate 4 of 4 directional calls best @ T+20▲ +13.43%Apr 8, 2026

Filters

Reports for MESO — sortable, filterable
	Type				Now
Apr 30, 2026 5w ago	Press Release BULLISH ★ 7/10	$15.67 $15.40	▼ −1.72%	▼ −6.95%	$13.80 (−11.93%)
Apr 29, 2026 6w ago	Press Release BULLISH ★ 7/10	$15.55 $14.76	▼ −5.08%	▼ −11.13%	$13.80 (−11.25%)
Apr 15, 2026 8w ago	Press Release BULLISH ★ 7/10	$15.75 $14.44	▼ −8.32%	▼ −14.36%	$13.80 (−12.38%)
Apr 10, 2026 8w ago	Press Release BULLISH ★ 8/10	$14.70 $14.51	▼ −1.29%	▼ −9.02%	$13.80 (−6.12%)
Apr 8, 2026 8w ago	Press Release BULLISH ★ 7/10	$13.92 $15.79	▲ +13.43%	▲ +4.89%	$13.80 (−0.86%)

US Market Status

Market Closed — Opens in 6h 57m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access